Successful treatment of Hepatitis C virus infection in a renal transplant patient with ribavirin and sofosbuvir: A case report

Nawfal R. Hussein, Zana Sidiq Mohammed Saleem

ABSTRACT

Introduction: In transplant patients, chronic hepatitis C virus could not be treated with classical interferon containing regimen as it is associated with serious complications including graft rejection. Though directly acting antivirals (DAAs) are potent for the treatment of HCV, such drugs are not been approved for the treatment of HCV in organ transplant subjects. Case Report: We described a 29-year-old female patient with hepatitis C virus genotype 4 infection who was treatment naïve. The patient was diagnosed with HCV and HBV years after renal transplant operation. Treatment with sofosbuvir and ribavirin allowed for rapid decrease of serum HCV RNA. The patient developed anemia in two different occasions during the treatment period and received blood transfusion. Sustained virologic response was achieved. Conclusion: The use of directly acting antivirals may allow a safe way to treat patients with renal transplant and chronic HCV. Such a treatment may improve the outcome of renal transplant in those patients with chronic HCV.
Successful treatment of Hepatitis C virus infection in a renal transplant patient with ribavirin and sofosbuvir: A case report

Nawfal R. Hussein, Zana Sidiq Mohammed Saleem

ABSTRACT

Introduction: In transplant patients, chronic hepatitis C virus could not be treated with classical interferon containing regimen as it is associated with serious complications including graft rejection. Though directly acting antivirals (DAAs) are potent for the treatment of HCV, such drugs are not been approved for the treatment of HCV in organ transplant subjects. Case Report: We described a 29-year-old female patient with hepatitis C virus genotype 4 infection who was treatment naïve. The patient was diagnosed with HCV and HBV years after renal transplant operation. Treatment with sofosbuvir and ribavirin allowed for rapid decrease of serum HCV RNA. The patient developed anemia in two different occasions during the treatment period and received blood transfusion. Sustained virologic response was achieved. Conclusion: The use of directly acting antivirals may allow a safe way to treat patients with renal transplant and chronic HCV. Such a treatment may improve the outcome of renal transplant in those patients with chronic HCV.

Keywords: Iraq, Ribavirin, Renal transplant, Sofosbuvir

INTRODUCTION

Chronic hepatitis C virus (HCV) infection remains a public health problem and an important cause of liver cirrhosis and transplant [1]. In comparison to uninfected subjects, HCV infection in renal transplant is associated with deleterious consequences such as a higher mortality rate due to different reasons [2–4] and an increased risk of allograft rejection [4]. The treatment of HCV infection in renal transplant patient with the aim of eliminating the risk of complications is highly desirable, however, this has been difficult to achieve. The treatment of HCV with classical interferon-containing regimens was fraught with poor tolerability, concern for interferon-associated acute graft rejection and ultimately very low success in achieving sustained virologic response. Therefore, the use of interferon free regimen is mandatory in such a case [5]. Outstanding development has been made in the treatment of chronic HCV with the development of potent directly acting antivirals (DAAs) [6]. These drugs may represent a promising mean for the treatment of HCV in renal transplant patients. However, trials are needed to study the efficacy and safety profile of DAAs in this group.
Recently, it has been shown that re-infection of a first liver graft can be prevented by sofosbuvir (SOF) and ribavirin (RBV) in subjects with compensated cirrhosis [7]. Here, to the best of our knowledge, we report the first case of a successful treatment with SOF and RBV for a renal transplant patient with chronic HCV genotype 4.

**CASE REPORT**

A 29-year-old Kurd female with renal transplant since 2004 was discovered with HBV in 2007 and HCV in 2013. The patient had been stable with normal ALT and AST. Then, in 2015, ALT started to fluctuate with a maximum read of 55 U/l. Total bilirubin, albumin and INR were normal (Table 1). The patient was sent to HBV and HCV RTPCR and results showed that the HBV level was undetected while HCV load was 3289285 IU/ml. HCV genotyping showed that the patient was infected with HCV genotype 4. Patient refused to get a liver biopsy done.

Immunosuppressive treatment consisted of mycophenolate 750 mg bid and tacrolimus 2 mg bid and prednisone 5 mg qd. For HBV, the patient received lamivudine 100 mg qd.

The patient discussed the new options of treatment of HCV with a multidisciplinary team. The patient decided to take treatment and would signed consent for that. The multidisciplinary team discussed the options and the availability of treatment in Iraq. Sofosbuvir was started at a dose of 400 mg qd plus RBV 1g qd. After starting treatment, the patient was followed up every four weeks. The rapid virologic response was achieved after four weeks though the viral load was still detectable. After eight weeks of treatment, the hemoglobin declined to 8.2 g/dl and blood transfusion was decided plus decreasing the dose of RBV to 400 mg qd (Table 1). Therefore, two units of blood were given to the patient. Four weeks later, the dose of RBV was returned back to 1 g qd and hemoglobin was measured after four weeks. Hemoglobin declined again to 7.2 and another two units of blood were given. The dose of RBV was decreased again into 400 mg qd. Then, RBV was increased gradually by adding 200 mg fortnightly. Then, hemoglobin never decreased to below 10 g/dl. HBV RTPCR was performed at 12th, 24th weeks and 12 weeks after stopping treatment and was negative in all occasions. Sustained virologic respond was achieved as

<table>
<thead>
<tr>
<th>Test/action</th>
<th>Before treatment</th>
<th>4 week</th>
<th>8 week</th>
<th>12 week</th>
<th>16 week</th>
<th>20 week</th>
<th>24 week</th>
<th>12 weeks after treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>36</td>
<td>27</td>
<td>13</td>
<td>10</td>
<td>12</td>
<td>12</td>
<td>13</td>
<td>22</td>
</tr>
<tr>
<td>AST</td>
<td>32</td>
<td>23</td>
<td>17</td>
<td>15</td>
<td>16</td>
<td>16</td>
<td>18</td>
<td>21</td>
</tr>
<tr>
<td>Albumin</td>
<td>4.2</td>
<td>3.82</td>
<td>4.2</td>
<td>4.1</td>
<td>4.1</td>
<td>4.3</td>
<td>4.1</td>
<td>4.2</td>
</tr>
<tr>
<td>TSB</td>
<td>0.9</td>
<td>0.9</td>
<td>0.7</td>
<td>1.3</td>
<td>1.2</td>
<td>1.1</td>
<td>0.8</td>
<td>0.9</td>
</tr>
<tr>
<td>INR</td>
<td>1.4</td>
<td>1.1</td>
<td>1.2</td>
<td>1.3</td>
<td>1.5</td>
<td>1.2</td>
<td>1.5</td>
<td>1.1</td>
</tr>
<tr>
<td>S. creatinine</td>
<td>1.3</td>
<td>1.2</td>
<td>1.25</td>
<td>1.38</td>
<td>1.3</td>
<td>1.18</td>
<td>1.3</td>
<td>1.1</td>
</tr>
<tr>
<td>HCV RTPCR</td>
<td>3289285</td>
<td>8571</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>11.3</td>
<td>10.5</td>
<td>8.5</td>
<td>10.1</td>
<td>7.2</td>
<td>10</td>
<td>10</td>
<td>12.2</td>
</tr>
<tr>
<td>Blood Transfusion</td>
<td>No</td>
<td>No</td>
<td>2 units</td>
<td>No</td>
<td>2 units</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>HBV RTPCR</td>
<td>Negative</td>
<td></td>
<td></td>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td>HBsAg</td>
<td>Positive</td>
<td></td>
<td></td>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
<td>Positive</td>
</tr>
<tr>
<td>HbeAg</td>
<td>Negative</td>
<td></td>
<td></td>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
<td>Negative</td>
</tr>
</tbody>
</table>
the viral load was not detected 12 weeks after stopping treatment (Table 1). Informed consent was taken from the patient for treating with new drugs not approved for treatment of HCV in transplant patients. Approval for treatment was taken from Hospital’s ethics committee.

**DISCUSSION**

The treatment of HCV after organ transplant is challenging. Interferon which has been used classically for the treatment of HCV can cause serious issues in organ transplant subjects. Recently, in non-transplant HCV-infected subjects, promising data about the use of interferon free regimen are available. In one study, 34 HCV genotype 1 infected liver transplant patients were recruited. Those patients were treated for 24 weeks with ombitasvir, dasabuvir and ribavirin. Sustained virologic response was achieved in 97% of them with minimum side effects [8]. There is an argument about the best timing for HCV treatment in renal transplant candidates (pre-transplant versus post-transplant) [9]. Usually, patients who need renal transplant go through a period of renal failure and dialysis. Currently, DAAs are not approved for the use in patients with renal failure. However, the optimum dosing of DAAs in such a group of patients might be available in near future [10]. In one study recruiting renal transplant subjects with chronic HCV, different regimens containing DAAs were used. The sustained virologic response was achieved in all patients including three patients who were treated with sofosbuvir and ribavirin. However, these patients (who received SOF plus RBV) were infected with the easier to treat genotype 2 [11]. Our patient was diagnosed with HCV genotype 4 and HBV co-infection. The liver function test had been stable for a while. Then, during follow-up sessions, ALT levels fluctuated with a maximum read of 55 U/l. Genotype study showed that the patient was infected with more difficult to treat genotype 4 which is the most common in our locality [12]. To the best of our knowledge, this is the first case of HCV genotype 4 and HBV co-infection to be treated with interferon free regimen. The anemia could have been avoided by gradual introduction of RBV. The renal function was stable throughout the study and no serious drugs interaction was recorded. Sustained virologic response was achieved as the viral load was undetectable 12 weeks after treatment. More studies are needed to investigate the efficacy and safety profile of such a regimen and if approved, it would prevent HCV related complication in renal transplant subjects and may improve graft survival.

**CONCLUSION**

This report showed that ribavirin and sofosbuvir can be used successfully in the treatment of hepatitis C virus infection in renal transplant recipient. Apart from anemia, this regimen seemed to be tolerable and without major interaction with immunosuppressant used and without serious negative impact upon the graft.

*********

**Acknowledgements**

We would like to thank all doctors and staff of Duhok transplant center for their cooperation.

**Author Contributions**

Nawfal R. Hussein – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Zana Sidiq Mohammed Saleem – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

**Guarantor**

The corresponding author is the guarantor of submission.

**Conflict of Interest**

Authors declare no conflict of interest.

**Copyright**

© 2016 Nawfal R. Hussein et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

**REFERENCES**


Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.